What is it about?
Proton pump inhibitor (PPI) drugs reduce gastric acid secretion and lead to an increase in serum gastrin levels. Many preclinical and some clinical researches have established some positive effects of gastrin or PPI therapy on glucose regulation. This study is about: may a PPI drug, esomeprazole, be effective for diabetes treatment? If yes, is there any association between this effect and gastrin levels?
Featured Image
Photo by Mykenzie Johnson on Unsplash
Why is it important?
The world is not succesful to treat diabetes. We already know that, these drugs are safe. If these drugs are effective for diabetes treatment, we will have one more drug group option to treat diabetes. And this research add valuable data to literature.
Perspectives
We now know how important the gastrointestinal system is on blood glucose regulation. Results regarding DPP-4 inhibitors, GLP-1 analogues and bariatric surgery are evident. Although there is evidence about gastrin, a GIS hormone, it is not sufficient. For this reason, my contribution to the very few studies on this subject makes me very happy. However, it is not enough. I hope this work will motivate further new works to be done.
Yusuf Bozkuş
Baskent Universitesi
Read the Original
This page is a summary of: Short-Term Effect of Hypergastrinemia Following Esomeprazole Treatment On Well-Controlled Type 2 Diabetes Mellitus: A Prospective Study, Endocrine Metabolic & Immune Disorders - Drug Targets, September 2020, Bentham Science Publishers,
DOI: 10.2174/1871530320666200129124555.
You can read the full text:
Contributors
The following have contributed to this page
